[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fMNfAAW9B9BWKyvogbE2Upkwlor1YDxSIwI52RcEIbFU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":46,"rows":53},"I.R.C.C.S. Fondazione Santa Lucia",[4],55,false,18,1,3076,2,48,[14,17,20,22,25,28,31,33],{"name":15,"count":16},"Stroke",14,{"name":18,"count":19},"Multiple Sclerosis",7,{"name":21,"count":19},"Alzheimer Disease",{"name":23,"count":24},"Parkinson Disease",5,{"name":26,"count":27},"Spinal Cord Injuries",4,{"name":29,"count":30},"Motor Disorders",3,{"name":32,"count":11},"Stroke, Ischemic",{"name":34,"count":11},"Severe Traumatic Brain Injury",[36,41],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06702124","A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease","2025-07","Rotigotine 4Mg\u002F24Hrs Patch",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06379997","Oral Supplementation Compared With Hyaluronic Acid Infiltration in Rotator Cuff Tendinopathies","2025-11-01","Intra-articular infiltration",[47,48,49,50,51,52],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[54,109,134,159,185,210,234],{"intervention":40,"totalTrials":11,"cells":55},{"EARLY_PHASE1":56,"PHASE1":59,"PHASE2":61,"PHASE3":95,"PHASE4":105,"NA":107},{"trials":57,"activeCount":58},[],0,{"trials":60,"activeCount":58},[],{"trials":62,"activeCount":58},[63],{"nctId":64,"briefTitle":65,"status":66,"phases":67,"primaryCompletion":68,"completion":69,"start":70,"enrollment":71,"conditions":72,"interventions":93},"NCT04937452","Dopaminergic Therapy for Frontotemporal Dementia Patients","COMPLETED",[49],"2023-12-30","2024-04-01","2021-06-03",75,[73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92],"Frontotemporal Dementia","Dementia","Aphasia, Primary Progressive","Pick Disease of the Brain","Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Neurocognitive Disorders","Mental Disorders","Neurodegenerative Diseases","Frontotemporal Lobar Degeneration","TDP-43 Proteinopathies","Proteostasis Deficiencies","Metabolic Disease","Aphasia","Speech Disorders","Language Disorders","Communication Disorders","Neurobehavioral Manifestations","Neurologic Manifestations",[40,94],"Rotigotine 6Mg\u002F24Hrs Patch",{"trials":96,"activeCount":9,"soonestReadout":39},[97],{"nctId":37,"briefTitle":38,"status":98,"phases":99,"primaryCompletion":39,"completion":100,"start":101,"enrollment":102,"conditions":103,"interventions":104},"RECRUITING",[50],"2026-04","2023-12-01",348,[21],[40],{"trials":106,"activeCount":58},[],{"trials":108,"activeCount":58},[],{"intervention":45,"totalTrials":9,"cells":110},{"EARLY_PHASE1":111,"PHASE1":113,"PHASE2":115,"PHASE3":117,"PHASE4":119,"NA":121},{"trials":112,"activeCount":58},[],{"trials":114,"activeCount":58},[],{"trials":116,"activeCount":58},[],{"trials":118,"activeCount":58},[],{"trials":120,"activeCount":58},[],{"trials":122,"activeCount":9,"soonestReadout":44},[123],{"nctId":42,"briefTitle":43,"status":98,"phases":124,"primaryCompletion":44,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":133},[52],"2025-12-31","2024-08-10",50,[129,130,131,132],"Tendinitis of Shoulder","Hyaluronic Acid","Dietary Supplements","Shoulder Pain",[45],{"intervention":135,"totalTrials":9,"cells":136},"Dopamine Agent",{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":143,"PHASE4":145,"NA":157},{"trials":138,"activeCount":58},[],{"trials":140,"activeCount":58},[],{"trials":142,"activeCount":58},[],{"trials":144,"activeCount":58},[],{"trials":146,"activeCount":58},[147],{"nctId":148,"briefTitle":149,"status":66,"phases":150,"primaryCompletion":151,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":156},"NCT03151460","Dopaminergic Modulation of Declarative Memory",[51],"2016-04","2014-09",40,[155],"Parkinson's Disease",[135],{"trials":158,"activeCount":58},[],{"intervention":160,"totalTrials":9,"cells":161},"Terazosin",{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":166,"PHASE3":168,"PHASE4":170,"NA":183},{"trials":163,"activeCount":58},[],{"trials":165,"activeCount":58},[],{"trials":167,"activeCount":58},[],{"trials":169,"activeCount":58},[],{"trials":171,"activeCount":58},[172],{"nctId":173,"briefTitle":174,"status":175,"phases":176,"primaryCompletion":177,"completion":177,"start":178,"enrollment":127,"conditions":179,"interventions":182},"NCT05855577","Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients","UNKNOWN",[51],"2026-05","2023-12",[23,180,181,86],"Gait Analysis","Therapy, Directly Observed",[160],{"trials":184,"activeCount":58},[],{"intervention":186,"totalTrials":9,"cells":187},"Ozanimod Oral",{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":194,"PHASE4":196,"NA":208},{"trials":189,"activeCount":58},[],{"trials":191,"activeCount":58},[],{"trials":193,"activeCount":58},[],{"trials":195,"activeCount":58},[],{"trials":197,"activeCount":58},[198],{"nctId":199,"briefTitle":200,"status":201,"phases":202,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":207},"NCT05777902","Multidimensional Integrated Assessment to Test the Efficacy and Response to Ozanimod in Multiple Sclerosis.","TERMINATED",[51],"2024-04-11","2023-01-31",30,[18],[186],{"trials":209,"activeCount":58},[],{"intervention":211,"totalTrials":9,"cells":212},"Rotigotine transdermal patch",{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":228,"PHASE4":230,"NA":232},{"trials":214,"activeCount":58},[],{"trials":216,"activeCount":58},[],{"trials":218,"activeCount":58},[219],{"nctId":220,"briefTitle":221,"status":66,"phases":222,"primaryCompletion":223,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":227},"NCT03250741","Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease",[49],"2018-11","2016-06",94,[21],[211],{"trials":229,"activeCount":58},[],{"trials":231,"activeCount":58},[],{"trials":233,"activeCount":58},[],{"intervention":94,"totalTrials":9,"cells":235},{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":246,"PHASE4":248,"NA":250},{"trials":237,"activeCount":58},[],{"trials":239,"activeCount":58},[],{"trials":241,"activeCount":58},[242],{"nctId":64,"briefTitle":65,"status":66,"phases":243,"primaryCompletion":68,"completion":69,"start":70,"enrollment":71,"conditions":244,"interventions":245},[49],[73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92],[40,94],{"trials":247,"activeCount":58},[],{"trials":249,"activeCount":58},[],{"trials":251,"activeCount":58},[]]